Focal Segmental Glomerulosclerosis (FSGS) Completed Phase 2 Trials for Abatacept (DB01281)

Also known as: Focal Glomerulosclerosis / Glomerulosclerosis, Focal / Focal Segmental Glomerulosclerosis / Glomerulosclerosis, Focal Segmental / APOL1-mediated focal segmental glomerulosclerosis / Focal & segmental glomerulosclerosis / Focal glomerular sclerosis (disorder) / Focal segmental glomerulosclerosis (disorder)

IndicationStatusPhase
DBCOND0038485 (Focal Segmental Glomerulosclerosis (FSGS))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02592798Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)Treatment